FFA
IKT icon

Farther Finance Advisors’s Inhibikase Therapeutics IKT Stock Holding History

Farther Finance Advisors’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$750 Buy
370
+301
+436% +$539 ﹤0.01% 5448
2026
Q1 		$125 Buy
+69
New +$123 ﹤0.01% 5486

Other funds holding IKT

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
SIC
SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Farther Finance Advisors's IKT Position: Q2 2026 in Review

Farther Finance Advisors increased its Inhibikase Therapeutics (IKT) stake by 436% in Q2 2026, buying an estimated $539 and bringing the position to 370 shares worth $750. The position accounts for ﹤0.01% of the portfolio, ranked #5448.

Farther Finance Advisors first reported a position in IKT in Q1 2026 and has held it in 2 quarters since. 5 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Farther Finance Advisors held 370 shares of Inhibikase Therapeutics worth $750 as of Q2 2026.
  • Farther Finance Advisors bought 301 Inhibikase Therapeutics shares in Q2 2026, an estimated $539.
  • Inhibikase Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5448 holding.
  • Farther Finance Advisors first reported a position in Inhibikase Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 5 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.